Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 146.64 $ -1.16 (-0.78 %)    

Wednesday, 05-Jun-2024 13:15:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 4.73 (1.04 %)
DIA $ 398.57 $ -0.74 (-0.19 %)
SPY $ 530.36 $ 2.08 (0.39 %)
TLT $ 91.26 $ 0.17 (0.18 %)
GLD $ 225.37 $ 1.11 (0.51 %)
$ 147.8
$ 147.88
$ 0.00 x 0
$ 152.00 x 239
$ 145.88 - $ 147.88
$ 141.57 - $ 170.63
8,876,441
na
359.17B
$ 0.49
$ 9.33
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-16-2024 12-31-2023 10-K
3 10-27-2023 10-01-2023 10-Q
4 10-27-2023 10-01-2023 10-Q
5 07-31-2023 07-02-2023 10-Q
6 04-28-2023 04-02-2023 10-Q
7 02-16-2023 01-01-2023 10-K
8 10-27-2022 10-02-2022 10-Q
9 07-29-2022 07-03-2022 10-Q
10 04-29-2022 04-03-2022 10-Q
11 02-17-2022 01-02-2022 10-K
12 10-29-2021 10-03-2021 10-Q
13 07-29-2021 07-04-2021 10-Q
14 04-30-2021 04-04-2021 10-Q
15 02-22-2021 01-03-2021 10-K
16 10-23-2020 09-27-2020 10-Q
17 07-24-2020 06-28-2020 10-Q
18 04-29-2020 03-29-2020 10-Q
19 02-18-2020 12-29-2019 10-K
20 10-28-2019 09-29-2019 10-Q
21 07-29-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-20-2019 12-30-2018 10-K
24 10-31-2018 09-30-2018 10-Q
25 08-02-2018 07-01-2018 10-Q
26 05-01-2018 04-01-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-02-2017 10-01-2017 10-Q
29 08-03-2017 07-02-2017 10-Q
30 05-08-2017 04-02-2017 10-Q
31 02-27-2017 01-01-2017 10-K
32 11-04-2016 10-02-2016 10-Q
33 08-04-2016 07-03-2016 10-Q
34 05-10-2016 04-03-2016 10-Q
35 02-24-2016 01-03-2016 10-K
36 10-30-2015 09-27-2015 10-Q
37 07-31-2015 06-28-2015 10-Q
38 05-01-2015 03-29-2015 10-Q
39 02-24-2015 12-28-2014 10-K
40 10-30-2014 09-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-submits-supplemental-nda-to-us-fda-seeking-expanded-pediatric-indication-for-hiv-1-therapy-prezcobix
Johnson & Johnson Submits Supplemental NDA...
06/04/2024 20:34:18

- Reuters

rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target
RBC Capital Reiterates Outperform on Johns...
06/04/2024 13:55:58

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

johnson--johnson-ordered-to-pay-260m-in-latest-talc-trial
Johnson & Johnson Ordered To Pay $260M In ...
06/04/2024 05:58:32

The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a pre...

Core News & Articles
Johnson & Johnson Announces Results From A...
06/03/2024 19:58:54

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patien...

johnson--johnson-announces-data-from-phase-3-perseus-study-showing-darzalex-based-regimens-significantly-improve-clinical-outcomes-in-both-transplant-eligible-and--ineligible-patients-who-are-newly-diagnosed-with-multiple-myeloma
Johnson & Johnson Announces Data From Phas...
06/03/2024 19:51:26

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-neg...

johnson--johnsons-late-breaking-results-from-its-paloma-2-study-of-subcutaneous-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumor-response-and-improved-safety-profile-in-patients-with-egfr-mutated-non-small-cell-lung-cancer
Johnson & Johnson's Late-Breaking Results ...
06/03/2024 18:33:12

administration in new Phase 2 dataCHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today new data from the...

johnson--johnson-at-asco-highlights-long-term-data-from-multiple-myeloma-drug-shows-sustained-deep-durable-responses-in-pretreated-patients
Johnson & Johnson At ASCO Highlights Long ...
06/03/2024 16:01:12

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with...

performance-comparison-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry
Performance Comparison: Johnson & John...
06/03/2024 15:00:42

Core News & Articles
WATCH: Dr. Fauci Testifies Live On COVID-1...
06/03/2024 14:49:38

https://www.youtube.com/watch?v=qCsEbq9SpsM 

Core News & Articles
U.S. FDA Staff Says Covid Vaccine Makers S...
06/03/2024 14:03:33

- Reuters - Reuters 

johnson--jonshon-announced-long-term-data-from-phase-12-majestec-1-study-of-tecvayli
Johnson & Jonshon Announced Long-Term Data...
06/03/2024 12:16:51

why-sarepta-therapeutics-stock-is-rising-today
Why Sarepta Therapeutics Stock Is Rising T...
05/30/2024 18:20:54

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added ...

Core News & Articles
Sarepta Therapeutics To Join S&P Midcap 40...
05/29/2024 21:20:31

 Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Mon...

johnson--johnsons-drug-seltorexant-aces-late-stage-depression-trial
Johnson & Johnson's Drug Seltorexant Aces ...
05/29/2024 16:55:12

Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depress...

johnson--johnson-pivotal-study-of-seltorexant-shows-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes
Johnson & Johnson Pivotal Study Of Seltore...
05/29/2024 16:18:40

https://www.jnj.com/media-center/press-releases/johnson-johnson-pivotal-study-of-seltorexant-shows-statistically-significant-an...

are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-what-you-can-do-to-prepare
Are Boomers Crashing The Economy Or Saving...
05/29/2024 14:51:04

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...

what-the-options-market-tells-us-about-johnson--johnson
What the Options Market Tells Us About Joh...
05/28/2024 17:16:20

johnson--johnson-to-acquire-numab-therapeutics-subsidiary-for-global-rights-to-nm26-in-atopic-dermatitis-for-125b-in-cash
Johnson & Johnson To Acquire Numab Therape...
05/28/2024 11:32:28

biden-administration-urges-supreme-court-review-in-terrorism-funding-lawsuit-against-pharma-companies
Biden Administration Urges Supreme Court R...
05/23/2024 18:00:16

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...

johnson--johnsons-bankruptcy-tactics-are-fraudulent-plaintiffs-accuse-company-of-defrauding-cancer-victims
Johnson & Johnson's Bankruptcy Tactics Are...
05/23/2024 15:26:45

Cancer victims have filed a lawsuit against Johnson & Johnson, accusing the company of fraudulently using a shell company&#...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION